A novel calcipotriol and betamethasone dipropionate (CAL/BDP) PAD-cream demonstrates greater improvements in daily activities and personal relationships than CAL/BDP gel/TS: A post-hoc analysis of DLQI outcomes from two phase 3 placebo-controlled randomized clinical trials in mild-to-moderate psoriasis

J Eur Acad Dermatol Venereol. 2024 Apr;38(4):e326-e328. doi: 10.1111/jdv.19600. Epub 2023 Nov 21.
No abstract available

Publication types

  • Letter

MeSH terms

  • Betamethasone* / analogs & derivatives
  • Betamethasone* / therapeutic use
  • Calcitriol* / analogs & derivatives
  • Clinical Trials, Phase III as Topic
  • Dermatologic Agents* / therapeutic use
  • Drug Combinations
  • Humans
  • Psoriasis* / drug therapy
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Substances

  • Betamethasone
  • betamethasone-17,21-dipropionate
  • calcipotriene
  • Calcitriol
  • Dermatologic Agents
  • Drug Combinations

Grants and funding